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Abstract:
Gum arabic, a branched polysaccharide was oxidized using periodate to generate reactive aldehdye
groups on the biopolymer. Primaquine, an 8-aminoquinoline was covalently coupled onto oxidized gum
arabic via imine bond and simultaneously fabricated into microspheres of less than 2 µm in size by heat
denaturation in a reverse emulsion of 1:1 light paraffin oil and toluene stabilized by sorbitan sesquioleate
as the surfactant.  The covalent binding of primaquine to the polysaccharide using the clinically used
water-soluble form of the drug, primaquine phosphate was achieved in the presence of borate buffer of
pH 11. Up to 35% of the drug could be bound to the polymer backbone depending on the concentration
of the drug employed initially and the degree of oxidation of the polysaccharide. Interestingly, both the
aliphatic and the hindered aromatic amino groups of primaquine were found to react with the aldehdye
functions through Schiff base formation leading to crosslinking of the polysaccharide with the drug
itself. In vitro release of the drug from microspheres into phosphate buffer (pH 7.4, 0.1 M) at 37ºC
showed that the release of primaquine from the matrix was slow, although gradually increased with time.
Maximum released was below 50% of the drug payload even after 10 days. A possible reason for the
poor hydrolytic susceptibility of the Schiff linkage is suggested based on the unequal reactivity of the
amino groups on primaquine and its relevance in possible therapeutic application of this polymer-drug
conjugate discussed.
Key words: gum arabic, polysaccharide, periodate oxidation, microspheres, drug delivery, primaquine,
8-aminoquinoline, sustained release, controlled release, polymer-drug conjugate.
Introduction:
Primaquine, an 8-aminoquinoline and some of
its derivatives are potent drugs in the treatment
of malaria as well as other parasitic diseases
such as Leishmaniasis (1 - 8). The clinical use
of primaquine however, poses problems due
to its toxicity. Primaquine may cause nausea,
abdominal pain and oxidant haemolysis with
methemoglobinemia,anemia, hemoglobinurea,
and is contraindicated in patients with different
variants of glucose-6-phosphate
dehydrogenase deficiency (1). In order to
improve the therapeutic efficacy of the drug
and diminish its toxicity, various approaches
have been examined. These include linking the
drug to a carrier protein such as albumin (9),
linking peptide derivatives of the drug onto
biodegradable polyacryl starch microspheres
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(10), encapsulation in polycyanoacrylate and
polylactide nanoparticles (11,3), in
erythrocytes (12) and in liposomes (13 - 14).
Polysaccharides constitute an important class
of biomaterials as most of them exhibit good
biocompatibility and biodegradability and a
number of drug delivery approaches have been
reported in the literature using polysaccharides
as drug carriers (15). To the best of our
knowledge, there is very little information in
the published literature on the use of
polysaccharides as drug delivery vehicles for
8-aminoquinoloines such as primaquine (10).
Gum arabic is a water-soluble natural
polysaccharide obtained from the exudate of
the acacia tree. This highly branched
polysaccharide is a complex mixture of Ca,
Mg and K salts of arabic acid that contains
galactose, rhamnose, glucuronic acid, 4-O-
methyl glucuronic acid and arabinose residues
(16). The molecular structure of gum arabic
consists of mainly three components, the major
component being arabinogalactan (90%)
having a low (0.5%) protein content, the
second being arabinogalactan  (< 10%) with a
high protein content (10%) and the third
component consisting less than 1% includes
glycoprotein having around 50% protein
content (17). It is extensively used as a food
additive (18), and is reported to be fermented
and metabolized in the caecum and the colon
(19 - 20).
Periodate oxidation of polysaccharides offers
a convenient route to synthesize polymer-drug
conjugates especially with drugs possessing
aliphatic amino functions via imino bonds with
the aldehyde groups of the oxidized
polysaccharide. In a recent report, the
synthesis of soluble amphotericin B-
arabinogalactan conjugate of reduced toxicity
and enhanced therapeutic efficacy was
demonstrated by periodate oxidation of the
polysaccharide followed by coupling the
amino-group containing antibiotic onto the
polymer (21). Primaquine contains an aliphatic
primary amino group as well as a hindered
aromatic amino group of unequal reactivity
(22) and therefore is an interesting candidate
for a similar approach in the preparation of a
polymeric drug. The Schiff’s reaction between
the amine and the aldehyde group is a rapid
reaction under appropriate conditions and it
was of interest to examine how the two
different amino groups in primaquine would
respond in the formation of the polymer-drug
conjugate and its hydrolytic stability, the latter
being the key-factor determining the release
profile of the drug from the conjugate.
Experimental:
Materials :
Gum Arabic (from acacia tree) of approximate
molecular weight 250,000 (Product No.G-
9752), primaquine phosphate, sorbitan
sesquioleate, borax (sodium tetraborate
decahydrate) and sodium m-periodate were
purchased from Sigma, USA. Dialysis tubing
(Spectra Por®, M.W.CO. 6000-8000) was from
Spectrum Laboratories Inc., CA, USA. Liquid
paraffin (Light, viscosity 18 cP at 30°C) was
from S.D. Fine Chemicals, Mumbai, India. All
other reagents such as methanol, acetone,
toluene, boric acid, disodium hydrogen
phosphate, monosodium hydrogen phosphate,
sodium chloride etc., were of analytical grade
and were procured locally. Borate buffer of
pH 11 was prepared by dissolving 6.18 g of
boric acid and 9.54 g of borax in 1L distilled
water and the pH was adjusted to 11 by the
addition of sodium hydroxide. Phosphate
buffered saline (PBS, pH 7.4, 0.1 M) was
prepared by dissolving 17.97 g of disodium
hydrogen phosphate, 5.73 g of monosodium
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hydrogen phosphate and 9 g of sodium
chloride in 1L distilled water.
Methods:
Oxidation of gum arabic
Gum arabic was oxidized using sodium m-
periodate.  Into 100 ml of a 10% solution of
gum arabic prepared in distilled water were
introduced different quantities of periodate
depending on the degree of oxidation desired
and the contents were stirred magnetically at
20°C in the dark for 6 h. The extent of
oxidation at the end of 6 h was determined by
iodometry (24). After the reaction, the contents
were dialysed against distilled water with
several changes of water over 2 days till the
dialysate was free from periodate (checked
with silver nitrate). The solution was then
frozen and lyophilized to dryness and stored
in the desiccator at 4°C until use. Typical
yields ranged from 75 to 80%.
Synthesis of gum arabic-primaquine
microspheres
Gum arabic-primaquine microspheres were
prepared by thermal denaturation process and
finally dehydrated using methanol and
acetone. Typically, 2 ml of a 10% solution of
oxidized gum arabic in borate buffer, was
added to 50 mL of a mixture of liquid paraffin
and toluene (1:1) containing 1 g of the oil
soluble surfactant, sorbitan sesquioleate in a
100 mL round-bottomed (RB) flask. A reverse
emulsion was formed by the dispersion of the
aqueous phase in the organic phase. To prepare
microspheres of small size (<2 µm), the
dispersion was cooled in ice and sonicated
using the Q-horn of a sonicator (Model 4710,
Cole-Parmer, IL, USA) at a power setting of
7 for 3 min. After sonication, a 20% aqueous
solution of primaquine phosphate equivalent
to 10, 20, 50 and 70% drug payload was
introduced and the contents were stirred at
1000 rev/min with a stainless steel half-moon
paddle stirrer in an oil bath maintained at 80°C
using a mechanical stirrer (Model RW-20, IKA
Labortechnik, Staufen, Germany) for 2 h.  The
contents were then centrifuged, washed with
5 mL aliquots of toluene (5x) till free from
oil, followed by 5 mL aliquots of methanol
(4x) and finally with 5 mL aliquots of acetone
(2x). The microspheres thus obtained were air-
dried. Yields were within 70-75%.
Estimation of drug content
Determination of extend of loading of
primaquine in microspheres was carried out
as follows. A known amount of drug-loaded
microspheres was digested using 5 mL of 6 N
HCl over a period of 5 h, the solution was
filtered through a 0.45 µm filter and the
absorbance was measured at 355 nm
spectrophotometrically (2) in a UV-Vis
spectrophotometer (Spectronic Genesys 2,
Milton Roy, NY, USA).
Electron microscopy
Scanning electron microscopy (SEM) was
performed using a Hitachi (Model S-2400,
Japan) instrument. Microspheres were
sprinkled onto double-sided tape, sputter
coated with gold and examined in the
microscope.
Particle size analysis
The particle size analysis of the microspheres
was carried out using SEM. SEM pictures of
microspheres were used to determine the
average particle size. The diameter of about
100 microspheres was measured from the
photomicrographs and the distribution was
plotted.
In vitro drug release
A known quantity of the primaquine-loaded
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microspheres was suspended in 50 mL PBS
in stoppered Erlenmeyer flasks. The flasks
were placed in a bath-shaker (Model SW-22,
Julabo Labortechnik, Seelbach, Germany),
thermostated at 37±1°C at a speed setting of
100 rpm. Aliquotes of 0.5 mL were with drawn
at various time intervals, and analyzed
spectrophotometrically for primaquine. A
constant volume in each flask was maintained
by replacing the aliquots with fresh buffer.
Results and discussion:
Branched polysaccharides are reported to be
better candidate materials for periodate
oxidation to as opposed to linear
polysaccharides such as dextran that undergoes
non-specific oxidations leading to
considerable reduction in molecular weight
after oxidation (25). When arabinogalactan
was oxidized using periodate at different molar
ratios of periodate and the polysaccharide, the
molecular weight of the oxidized product was
reported to be stable (21). The high yield of
the product after oxidation also is a pointer to
a stable molecular weight as small fragments
generated by non-specific oxidation of the
back bone polymer would freely diffuse
through the dialysis membrane leading to
drastic reduction in the yield.
The oxidized gum arabic was also found to be
soluble in aqueous solutions although the
solubility was not quite as high as that of gum
arabic. Solutions of oxidized gum arabic at
10% concentration were clear and viscous and
these solutions were employed in the synthesis
of microspheres. The microspheres were
prepared by conjugating the drug to the
polymer and simultaneously fabricating the
microspheres by heat denaturation.
Primaquine was used in its commercially
available form, the diphosphate salt, the free
primaquine being insoluble in water (22). The
reaction was carried out in borate buffer of
pH 11 as this buffer has been reported to be
most efficient in the formation of Schiff base
linkages between the amino group of the drug
and the aldehdye group in oxidized
arabinogalactan (21).
The microspheres obtained were quite
spherical in shape and free flowing. Figure 1
shows the SEM of the microspheres and the
particle size distribution of the same as
depicted in Fig 2. Virtually all microspheres
were below 2 µm in size.
Fig 1: Scanning electron micrograph
of microspheres
Fig 2:  The particle size distribution
of the microspheres
Estimation of the drug content of the
microspheres after acid digestion showed that
the incorporation efficiency the microsphere
preparations is not high at all initial drug
contents (Table 1).
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Table 1: Incorporation efficiency of primaquine in oxidized gum arabic microsphere
Percentagex Theoretical drug Actual drug Incorporation
oxidationof gum arabic content (%) content (%) efficiency (%)
50 70 24.7 ± 3.7 35.3 ± 5.2
50 50 8.5 ± 1.3 17.0 ± 2.5
50 20 4.7 ± 0.5 23.5 ± 2.3
20 50 12.8 ± 1.4 25.6 ± 2.6
20 10 3.5 ± 0.4 35.0 ± 2.8
At the alkaline pH, the free primaquine
dissociated from the diphosphate salt would
enter into reaction with the aldehdye groups
of the oxidized polysaccharide leading to the
formation of Schiff base linkage between the
drug and the polysaccharide and we expected
the covalent immobilization of the drug onto
the polymer to be high. During the
incorporation process, at the relatively high
temperature employed, it was seen that the free
primaquine generated by the dissociation of
the phosphate salt migrating into the non-
aqueous dispersion medium as evidenced by
the yellow coloration of the medium.
However, reasonable, therapeutically
significant loadings were obtained by the
process employed.
In vitro release of primaquine from the
microspheres was examined in phosphate
buffer at 37°C. Release from 50% oxidized
gum arabic was slower (Fig 3) compared to
the release from 20% oxidized gum arabic (Fig
4). For instance, while only about 10% of the
drug was released from 50% oxidized matrix
having a drug pay load of 4.7%, over 30% was
released from 20% oxidized matrix having
similar pay load. With both matrices, as
expected, increased release was seen with
increase in amount of drug initially present.
We believe that slow release observed from
matrices having a higher degree of oxidation
is due to the better drug conjugation onto the
polymer because of the large number of
aldehyde groups present.
Fig 3: Release of primaquine from microspheres
obtained from 50% oxidized gum arabic
Fig 4: Release of primaquine from microspheres
obtained from 20% oxidized gum Arabic
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The slow release seen in the case of all
microsphere preparations into phosphate
buffer pointed to the rather poor hydrolytic
susceptibility of the Schiff linkages between
the drug and the polymer. Primaquine contains
two amino groups and both are not equally
reactive. When primaquine was reacted with
a highly reactive diacid chloride such as
sebacoyl chloride in chloroform, instead of a
polyamide, the product obtained was
diprimaquine sebacamide demonstrating that
the hindered aromatic amino group did not
enter into reaction with the acid chloride (22).
In case of Schiff base formation between the
aldhehyde and the amino groups, it is known
that both primary and secondary amino groups
are reactive and when there is an aryl group
on the nitrogen, the resultant products are
reported to be quite stable (26). In order to
examine whether both the amino groups are
reacting with the aldehdye groups in oxidized
gum arabic, we simply mixed primaquine
phosphate and oxidized gum arabic in borate
buffer and obtained a crosslinked gel that was
insoluble in water. This observation suggested
that primaquine actually crosslinks the
oxidized polysaccharide. Conjugation only
through the aliphatic amino group onto the
polymer should have resulted in a soluble
polymer-drug conjugate as in the case of
amphotericin B and arabinogalactan reported
by earlier workers (21).
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